Dr Alan Olivero is a consultant specialising in drug discovery and development. In 2018 he retired from Genentech, Inc., where he worked for 25 years, rising to the level of Senior Director, of Discovery Chemistry and Head of Research Operations. During his time at Genentech, he oversaw much of the medicinal chemistry conducted at Genentech, led research teams for eight clinical candidates and, as Head of Research Operations, additionally oversaw the company’s research budget, headcount, and research facilities.
Dr Olivero is an expert on intracellular signalling pathways and was the team leader for Genentech’s PI3K franchise. He has a specialist interest in brain cancer and is a coinventor of paxalisib (formally GDC-0084). He led the early development of paxalisib and was responsible for bringing the drug into human trials.
Dr. Olivero has a BS degree in chemistry from Stanford University, completed postgraduate work in synthetic organic chemistry at the Swiss Federal Institute of Technology in Zurich (ETHZ), and received his PhD in organic chemistry from Stanford University in 1988. He has co-authored numerous scientific publications and is a named inventor on over 40 patents.